On his second day in hospital, the patient was started on gefitinib at 250 mg/day, given that this drug has been shown to be safe and effective in EGFR mutation–positive NSCLC patients with a poor PS [3]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.